Published Articles & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

Placebo/Active Controlled, Safety, Pharmaco-Kinetic/Dynamic Study of INP105 (POD olanzapine) in Healthy Adults

March 2019 - A 2008 survey of emergency department staff (ED) found that 65% had witnessed physical attacks, 32% reported at least one verbal threat per day, and 18% had been assaulted at least once with a weapon. While many…

Development of a Precision Olfactory Delivery (POD)-Olanzapine Drug-Device Product for Agitation

March 2019 - Agitation is a cluster of behaviors observed in multiple psychiatric diseases, which can increase the likelihood of violent behavior. Atypical antipsychotics, including oral and intramuscular (IM) olanzapine (OLZ), have been approved for chronic and acute agitation treatment,…

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic (PK/PDyn) Study of INP103 (POD® L dopa) Administered in the presence of Benserazide, to L-dopa Responsive Parkinson’s Disease (PD) Patients (THOR 201)

August 2018 - This study, administering L-dopa to the vascular-rich upper nasal space with the novel POD device should guide further clinical development for an easy self or care-giver administered, rapidly effective treatment to abort OFF episodes in PD.

27 28 29